DOI:
10.1039/C6RA22603E
(Paper)
RSC Adv., 2016,
6, 105433-105441
Efficient synthesis of novel 1,2,3-triazole-linked quinoxaline scaffold via copper-catalyzed click reactions†
Received
9th September 2016
, Accepted 27th October 2016
First published on 28th October 2016
Abstract
In this work, new derivatives of the 1,2,3-triazole-linked quinoxaline ring system are prepared by the reaction of 2-chloro-3-(prop-2-ynyloxy)quinoxaline or 2,3-bis(prop-2-ynyloxy)quinoxaline with aromatic azides via copper-catalyzed azide-alkyne cycloaddition reactions in the presence of the Schiff base ligands. These reaction procedures have the advantages of high-to-excellent yields, short reaction times, mild experimental conditions, and operational simplicity. The synthesized compounds were screened against the three bacterial strains Micrococcus luteus, Pseudomonas aeruginosa, and Bacillus subtilis. The anti-bacterial activity of 6b against P. aeruginosa was better than that for the standard drug (tetracycline).
Introduction
Click chemistry offers a highly efficient technique for connecting two potential building blocks to other functional groups under mild conditions with high tolerance.1–3 Click reaction has been widely applied to the synthesis of macromolecules4 and functionalization of biomolecules.5 1,2,3-Triazole compounds have an important role not only in organic chemistry but also in medicinal chemistry, drug discovery, agrochemicals, and also as dyes due to their easy synthesis by click chemistry and interesting features as well as multiple biological activities.6,7 The 1,2,3-triazole framework constitutes the structure of a large variety of bioactive molecules such as the anti-fungal,8 anti-bacterial,9,10 anti-allergic,11 anti-HIV,12,13 anti-tubercular,14,15 and anti-inflammatory agents.16
Quinoxaline and its derivatives display a broad biological activities, and have been used as the anti-cancer,17 anti-viral,18 anti-bacterial,19 and kinase-inhibition agents.20 They have contributed to their usefulness in the combinatorial drug discovery libraries.21–26 The quinoxaline skeleton is an important part of a number of antibiotics such as echinomycin, actinomycin, and leromycin that are known to inhibit the growth of Gram-positive bacteria, and to be active against various transplantable tumors.27,28
Binding 1,2,3-triazole moieties to other pharmacophores via copper-catalyzed click reactions is important for the synthesis of biologically-active compounds. A series of 6,7-dichloro-1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones have been prepared, in which the 5-position of the ring in these compounds has been occupied by a heterocyclylmethyl or a 1-(heterocyclyl)-1-propyl group. The most anti-tumor activity potent available in this series is 6,7-dichloro-5-[1-(1,2,4-triazol-4-yl)propyl]-1,4-dihydro-(1H,4H)-quinoxaline-2,3-dione.29 Therefore, the synthesis of 1,2,3-triazole linked to the quinoxaline scaffold has gained prominence in the synthetic organic as well as medicinal chemistry.
Copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions have several priorities over the thermal version30 including selectivity, increased reactivity of deactivated alkynes, and high yields.31 In continuation of our studies directed toward the efficient synthesis of biologically-active molecules with a quinoxaline ring,32–34 we decided to synthesize new derivatives of the 1,2,3-triazole-linked quinoxaline ring system via the copper-catalyzed click reactions.
Results and discussion
Treatment of 2,3-dichloroquinoxaline (1) with prop-2-yn-1-ol (2) in DMF in the presence of t-BuOK, as a base, afforded 2-chloro-3-(prop-2-ynyloxy)quinoxaline (3) in good yield (Scheme 1). The 1H NMR spectrum of 3 showed a triplet for the CH proton at δ 3.73, a doublet for the CH2 protons at δ 5.18, and a multiplet for the aromatic protons of the quinoxaline ring at δ 7.55–8.10.
 |
| Scheme 1 Synthesis of 2-chloro-3-(prop-2-ynyloxy)quinoxaline by reaction of 2,3-dichloroquinoxaline with prop-2-yn-1-ol. | |
Similarly, the reaction of 2,3-dichloroquinoxaline (1) with two equivalents of prop-2-yn-1-ol (2) afforded 2,3-bis(prop-2-ynyloxy)quinoxaline (4) under the same experimental conditions (Scheme 2).
 |
| Scheme 2 Synthesis of 2,3-bis(prop-2-ynyloxy)quinoxaline by reaction of 2,3-dichloroquinoxaline with 2 eq. of prop-2-yn-1-ol. | |
The click reaction of 2-chloro-3-(prop-2-ynyloxy)quinoxaline (3) with 1-azido-3-nitrobenzene (5a) in the presence of 5 mol% of CuSO4 and 10 mol% of sodium ascorbate only yielded 40% of 2-chloro-3-[(1-(3-nitrophenyl)-1H-1,2,3-triazol-4-yl]methoxy)quinoxaline (6a), as the desired product (Table 1, entry 1). The effects of various amounts of the catalyst, solvent, and ligand, and also the temperature were studied, and the results obtained were tabulated in Table 1. The reaction most effective in the presence of 10 mol% of CuSO4 and 20 mol% of sodium ascorbate at 78 °C in ethanol, giving the desired product with an excellent yield (98%) (Table 1, entry 2).
Table 1 Effects of various amounts of catalyst and solvent, and temperature on reaction of 2-chloro-3-(prop-2-ynyloxy)quinoxaline (3) with 1-azido-3-nitrobenzene (5c)a
A large amount of a heavy metal catalyst is used in the classic copper-catalyzed click reactions, whereas Cu salts are toxic, pollute the biologically relevant compounds, and their complete removal from the reaction products is difficult. This problem inhibits the utilization of the click reactions in the biomedicine science. The nitrogen ligands allow the use of copper catalysts in reduced amounts compared to the original classic catalyst (CuSO4 and sodium ascorbate), which is still the most commonly utilized catalyst but in much larger quantities that are often even stoichiometric or superior to stoichiometry.35 Ligands can be used to (a) prevent the formation of unreactive polynuclear copper(I) acetylides; (b) facilitate coordination of the azide to the copper center at the ligand exchange step; and (c) increase the solubility of the copper complex to deliver higher solution concentrations of the necessary Cu(I)-species.36 A number of researchers have efficiently decreased the required amount of the copper catalyst for the click reactions by the usage of ligands.37 Recently, Astruc and co-workers have used the dendrimer ligand to decrease the copper catalyst used to the ppm scale in simple click reactions.38 In order to decrease the amount of the copper catalyst, we decided to use the Schiff base ligands salen (L1) and salophen (L2) as additive in the reaction. We also screened metformine (L3) as the ligand. Surprisingly, in the presence of L1 and with 2.5 mol% of Cu(OAc)2, the reaction proceeded effectively and was completed to afford the desired product in a 95% yield (Table 1, entry 21). Therefore, the optimal reaction conditions were 2.5 mol% of Cu(OAc)2, 5 mol% of sodium ascorbate and 2.5 mol% of salophen (L2) at 78 °C in ethanol (Table 1, entry 21).
For the synthesis of 2,3-bis[(1-aryl-1H-1,2,3-triazol-4-yl)methoxy]quinoxalines (7) from 2,3-bis(prop-2-ynyloxy)quinoxaline (4) and aromatic azides (5), the optimization was made in the same fashion, and the results obtained were tabulated in Table 2. The best reaction conditions were 5 mol% of CuI and 5 mol% of salen (L1) in DMF at 50 °C (Table 2, entry 22).
Table 2 Effects of various amounts of catalyst and solvent, and temperature on reaction of 2,3-bis(prop-2-ynyloxy)quinoxaline (4) with 1-azido-3-nitrobenzene (5a)a
In order to explore the scope and generality of these protocol, various aromatic azides were used as the substrates for the synthesis of substituted 2-chloro-3-[(1-(aryl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxalines (6a–e) and 2,3-bis[(1-(aryl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxalines (7a–e) (Schemes 3 and 4). The results obtained were tabulated in Tables 3 and 4.
 |
| Scheme 3 Synthesis of 2-chloro-3-[(1-aryl-1H-1,2,3-triazol-4-yl]methoxy]quinoxalines (6) by reaction of 2-chloro-3-(prop-2-ynyloxy)quinoxaline (3) with an aromatic azide (5) via a copper-catalyzed click reaction. | |
 |
| Scheme 4 Synthesis of 2,3-bis[(1-aryl-1H-1,2,3-triazol-4-yl)methoxy]quinoxalines (7) by reaction of 2,3-bis(prop-2-ynyloxy)quinoxaline (4) with 2 eq. of an aromatic azide (5) via a copper-catalyzed click reaction. | |
Table 3 Synthesis of 2-chloro-3-[(1-(aryl)-1H-1,2,3-triazol-4-yl]methoxy)quinoxalinesa
Entry |
Azide |
Product |
Time (h) |
Yield (%) |
Reaction conditions: 3 (0.5 mmol), 5 (0.5 mmol), CuI (2.5 mol%), salophen (2.5 mol%), EtOH (4 mL), 78 °C. |
1 |
 |
 |
2 |
95 |
2 |
 |
 |
2.5 |
85 |
3 |
 |
 |
2.5 |
92 |
4 |
 |
 |
1 |
87 |
5 |
 |
 |
1.5 |
97 |
Table 4 Synthesis of 2,3-bis[(1-(aryl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxalinesa
Entry |
Azide |
Product |
Time (h) |
Yield (%) |
Reaction conditions: 3 (0.5 mmol), 5 (1 mmol), CuI (5 mol%), salophen (5 mol%), DMF (3 mL), 50 °C. |
1 |
 |
 |
4 |
90 |
2 |
 |
 |
5 |
80 |
3 |
 |
 |
4 |
88 |
4 |
 |
 |
3 |
95 |
For the synthesis of a variety of 2-chloro-3-(1H-1,2,3-triazol-4-ylmethoxy)quinoxaline derivatives (6), we decided to replace the chlorine atom in the 2-position of the ring in these compounds by amine nucleophiles (Scheme 5). Nucleophilic substitution of the chlorine atom in 6 was performed easily using secondary amines such as dimethyl amine, morpholine, and piperidine to afford 8 in DMF. The results obtained were tabulated in Table 5.
 |
| Scheme 5 Nucleophilic substitution of 2-chloro-3-[(1-(aryl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxalines (6) with nucleophiles. | |
Table 5 Synthesis of 2-amino-3-[(1-(aryl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxalinesa
Aryl halide |
NuH |
Product |
Time (h) |
Yield (%) |
Reaction conditions: 6 (1 mmol), NuH (2.2 mmol), DMF (5 mL), 70 °C. |
6a |
 |
 |
5 |
87 |
6b |
 |
 |
3 |
90 |
6c |
 |
 |
4 |
89 |
The copper-catalyzed click reaction catalytic cycle mechanism comprises the multi-general steps shown in Scheme 6: (a) formation of copper(I) acetylide A; this step occurs through a π-alkyne copper complex intermediate. (b) The azide is then activated by coordination to copper(I), forming intermediate B. (c) The first C–N bond formation affords the six-membered ring copper metallacycle C. (d) Cyclization takes place to yield the copper triazole intermediate D. (e) Proteolysis of the Cu–C bond gives the triazole product, and regenerates the catalyst. Each stage involves a multi-nuclear Cu species.1c,2b
 |
| Scheme 6 Proposed mechanism for the copper catalyzed click reactions. | |
The synthesized compounds were tested in vitro for their anti-bacterial activity against the microorganisms Micrococcus luteus, Bacillus subtilis (Gram positive) and Pseudomonas aeruginosa (Gram negative) using tetracycline as a standard anti-bacterial agent, and the results obtained were tabulated in Table 6. Their anti-bacterial activities were determined by a well-diffusion method at a concentration of 4000 μg mL−1. According to these results, 6b showed the highest anti-bacterial activity against P. aeruginosa (20) among all of the compounds. In addition, the anti-bacterial activity of this compound was better than the standard drug tetracycline. Moreover, 6b showed a significant inhibition activity against M. luteus (16). Also 4, 6a, 7a, 7b, and 8b possessed higher anti-bacterial activities against P. aeruginosa. Only 4 and 8a showed good anti-bacterial activity against B. subtilis.
Table 6 Anti-bacterial activities of some selected compounds (4000 μg mL−1) as inhibition zone (in mm)
Entry |
Compound |
M. luteus |
B. subtilis |
P. aeruginosa |
Negative control. Positive control. |
1 |
3 |
— |
— |
— |
2 |
4 |
8 |
9 |
7 |
3 |
6a |
9 |
— |
9 |
4 |
6b |
16 |
— |
20 |
5 |
6c |
7 |
— |
— |
6 |
6d |
— |
— |
— |
7 |
7a |
— |
— |
7 |
8 |
7b |
— |
— |
8 |
9 |
7c |
7 |
— |
— |
10 |
7d |
8 |
— |
— |
11 |
8a |
— |
8 |
— |
12 |
8b |
— |
— |
7 |
13 |
DMSOa |
— |
|
— |
14 |
Tetracyclineb |
41 |
15 |
13 |
MIC is defined as the lowest concentration of the compound at which the growth is inhibited after 24 h of incubation in a rotatory shaker at 37 °C. All the newly synthesized compounds were evaluated for their anti-microbial activity against Micrococcus luteus using a micro-method for the determination of the minimum inhibitory concentration (MIC). The MIC values for the active compounds are summarized in Table 7. Compound 7c was the most active compound against this strain in the set (MIC = 31.25 mmol L−1), whereas 6c and 6d were only weakly active against this bacterium (MIC = 500 mmol L−1).
Table 7 In vitro anti-microbial activity of all products expressed as MIC (mmol L−1)
Entry |
Compound |
MIC |
1 |
6a |
250 |
2 |
6b |
62.5 |
3 |
6c |
500 |
4 |
6d |
500 |
5 |
7a |
250 |
6 |
7b |
125 |
7 |
7c |
31.25 |
8 |
7d |
125 |
9 |
7e |
62.5 |
10 |
Tetracycline |
31.25 |
Conclusion
We developed an efficient procedure for the synthesis of a 1,2,3-triazole-linked quinoxaline ring system in high-to-excellent yields by the reaction of the quinoxaline acetylenic compound 2-chloro-3-(prop-2-ynyloxy)quinoxaline or 2,3-bis(prop-2-ynyloxy)quinoxaline with aromatic azides via the copper-catalyzed click reactions in the presence of Schiff base ligands. Short reaction time, simple operation, and easy workup are some advantages of this protocol. All the new 1,2,3-triazole-linked quinoxaline scaffold formed were screened for their in vitro anti-bacterial activity against Gram-positive and Gram-negative bacteria using a well-diffusion method.
Experimental part
General information
The materials and solvents used were commercially available. Melting points were determined on an Electrothermal 9100 melting point apparatus. Products were characterized by melting point determinations, and IR, 1H NMR, 13C NMR, and mass spectroscopic techniques. IR spectra were obtained on a Shimadzu IR-470. NMR data were recorded in CDCl3 and DMSO on a Bruker Avance 400 MHz spectrometer. The mass spectra were measured on a quadru pole 5973 Network Mass Selective Detector. Thin-layer chromatography was performed on a 0.25 mm film of silica gel that contained a fluorescent indicator UV 254 supported on an aluminum sheet (Sigma-Aldrich).
Anti-bacterial assay
The anti-bacterial activities of the new compounds were evaluated biologically using a well-diffusion method against M. luteus (ATCC 4698), P. aeruginosa (ATCC 27853), and B. subtilis (DSM 6887) supplied from Iranian biological resource center, Tehran, Iran. First the nutrient agar and nutrient broth cultures were prepared according to the manufactures' instructions, which were then incubated at 37 °C. After incubation for an appropriate time period, a suspension of 40 μL of each bacterium was added to the nutrient agar plates. Cups (5 mm in diameter) were cut in the agar using a sterilized glass tube. Each well-received 30 μL of the test compounds at a concentration of 4000 μg mL−1 in DMSO. Then the plates were incubated at 37 °C for 24 h, after which time, the inhibition zone was measured in mm. The results obtained were reported as the inhibition zone in mm. The anti-bacterial activity of each compound was compared with that for tetracycline as the standard drug. DMSO was used as the negative control.
Synthesis of 2-chloro-3-(prop-2-ynyloxy)quinoxaline (3). Prop-2-yn-1-ol 2 (2.1 mmol) was added slowly to a stirring mixture of 1,2-dichloro quinoxaline 1 (2 mmol) and t-BuOK (2.1 mmol) in dry DMF (4 mL) at room temperature. The reaction mixture was warmed to 70 °C, and stirring was continued until the disappearance of compound 1 (monitored by TLC). The solvent was evaporated to dryness, the crude product was washed with H2O, and the precipitate formed was purified by recrystallization from ethanol.Mp, 120 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 3.70 (t, J = 2.4 Hz, 1H, 5-H), 5.22 (d, J = 2.4 Hz, 2H, 6-H), 7.70 (td, J = 7.6 Hz, J = 1.6 Hz, 1H, 2-H), 7.80 (td, J = 7.7 Hz, J = 1.4 Hz, 1H, 3-H), 7.87 (dd, J = 8.2 Hz, J = 1.2 Hz, 1H, 4-H), 7.95 (dd, J = 8.2 Hz, J = 1.2 Hz, 1H, 1-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 55.7, 78.6, 79.1, 127.0, 128.1, 128.6, 131.3, 138.3, 138.7, 139.0, 151.9 ppm; IR (KBr):
= 3290, 2960, 2100, 1560, 1480, 1323 cm−1.
Synthesis of 2,3-bis(prop-2-ynyloxy)quinoxaline (4). Prop-2-yn-1-ol (2) (4.2 mmol) was added slowly to a stirring mixture of 1,2-dichloro quinoxaline (1) (2 mmol) and t-BuOK (4.2 mmol) in dry DMF (4 mL) at room temperature. The reaction mixture was warmed to 70 °C, and stirring was continued until the disappearance of compound 1 (monitored by TLC). The solvent was evaporated to dryness, the crude product was washed with H2O, and the precipitate formed was purified by recrystallization from CH3CN.Mp, 180–181 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 3.66 (t, J = 2.4 Hz, 2H, 3-H), 5.19 (d, J = 2.4 Hz, 4H, 4-H), 7.59–7.61 (m, 2H, 1-H), 7.78–7.81 (m, 2H, 2-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 54.7, 78.8, 79.0, 126.7, 127.8, 136.8, 148.3 ppm; IR (KBr):
= 3298, 2965, 2110, 1564, 1480, 1320 cm−1.
General procedure for synthesis of 2-chloro-3-[(1-(aryl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxaline
To a mixture of 3 (0.5 mmol) and an aromatic azide (5) (0.5 mmol) in ethanol (4 mL), were added CuI (2.5 mol%) and salophen (2.5 mol%). The resulting mixture was stirred at 78 °C until the disappearance of compound 3 (monitored by TLC). Upon completion of the reaction, the solvent was evaporated to dryness, the crude product was washed with a (1
:
1) mixture of H2O and conc. NH3 to remove the catalyst. The precipitate formed was collected, dried, and finally purified by recrystallization from CH3CN to give 6.
2-Chloro-3-[(1-(3-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxaline (6a). Mp, 219–220 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 5.80 (s, 2H, 6-H), 7.74 (td, J = 7.6 Hz, J = 1.4 Hz, 1H, 2-H), 7.85 (td, J = 7.6 Hz, J = 1.4 Hz, 1H, 3-H), 7.93 (t, J = 8.2 Hz, 1H, 2′-H), 7.99–8.03 (m, 2H, 1′, 3′-H), 8.36 (ddd, J = 8.2 Hz, J = 2.2 Hz, J = 0.8 Hz, 1H, 4-H) 8.44 (ddd, J = 8.4 Hz, J = 1.6 Hz, J = 0.8 Hz, 1H, 1-H), 8.76 (t, J = 2.2 Hz, 1H, 4′-H), 9.25 (s, 1H, 5-H), ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 60.8, 115.5, 123.8, 124.6, 126.8, 127.2, 128.1, 128.5, 131.3, 132.0, 137.5, 138.4, 139.0, 139.3, 143.6, 149.0, 152.5 ppm; IR (KBr):
= 3090, 2980, 1561, 1520, 1480, 1340 cm−1. MS (m/z): 382 M+.
2-Chloro-3-[(1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxaline (6b). Mp, 173–175 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 5.79 (s, 2H, 6-H), 7.74–8.02 (m, 7H), 8.25 (dd, J = 7.6 Hz, J = 0.8 Hz, 1H, 4′-H), 8.93 (s, 1H, 5-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 60.7, 126.0, 127.30, 127.35, 128.1, 128.2, 128.5, 129.4, 131.3, 131.8, 134.9, 138.4, 139.0, 139.2, 142.8, 144.5, 152.5 ppm; IR (KBr):
= 3110, 3050, 2920, 1605, 1545, 1528, 1420, 1360, 1320, 1220, 1060, 740 cm−1. MS (m/z): 382 M+.
2-Chloro-3-[(1-(3-chloro-4-nitrophenyl)-1H-1,2,3-triazol-4-yl]methoxy)quinoxaline (6c). Mp, 238 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 5.79 (s, 2H, 6-H), 7.74 (td, J = 7.7 Hz, J = 1.2 Hz, 1H, 2-H), 7.85 (td, J = 7.7 Hz, J = 1.2 Hz, 1H, 3-H), 7.97–8.06 (m, 3H, 1,4,2′-H), 8.31 (dd, J = 8.8 Hz, J = 2.8 Hz, 1H, 1′-H), 8.72 (d, J = 2.8 Hz, 1H, 3′-H), 9.16 (s, 1H, 5-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 59.5, 115.3, 123.6, 124.0, 125.1, 125.7, 126.2, 126.7, 127.2, 132.0, 135.3, 137.5, 138.8, 144.2, 147.4, 148.9, 149.4 ppm; IR (KBr):
= 3100, 2960, 1528, 1440, 1347, 1240 cm−1. MS (m/z): 416 M+.
2-Chloro-3-[(1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxaline (6d). Mp, 245–246 °C; 1H NMR (400 MHz, CDCl3): δ = 5.80 (s, 2H, 6-H), 7.74 (td, J = 7.6 Hz, J = 1.2 Hz, 1H, 2-H), 7.85 (td, J = 7.6 Hz, J = 1.6 Hz, 1H, 3-H), 8.00–8.04 (m, 2H, 1,4-H), 8.27 (d, J = 9.2 Hz, 2H, 1′-H), 8.47 (d, J = 10.4 Hz, 2H, 2′-H), 9.22 (s, 1H, 5-H) ppm; IR (KBr):
= 3120, 2966, 1598, 1523, 1475, 1323 cm−1. MS (m/z): 382 M+.
2-Chloro-3-[(1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxaline (6e). Mp, 198 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 5.70 (s, 2H, 6-H), 7.56–7.65 (m, 4H, Ar-H), 7.88–7.92 (m, 3H, Ar-H), 8.04 (s, 1H, 4′-H), 9.05 (s, 1H, 5-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 59.7, 119.3, 120.5, 124.4, 126.8, 127.6, 129.1, 132.0, 134.6, 137.0, 138.0, 143.5, 149.0 ppm; IR (KBr):
= 3108, 2952, 1597, 1480, 1315, 1200 cm−1. MS (m/z): 371 M+.
General procedure for synthesis of 2,3-bis[(1-(aryl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxaline
To a mixture of 4 (0.5 mmol) and an aromatic azide (5) (1 mmol) in DMF (3 mL) were added CuI (5 mol%) and salen (5 mol%). The resulting mixture was stirred at 50 °C until the disappearance of compound 5 (monitored by TLC). Upon completion of the reaction, to the resulting mixture was added a (1
:
1) mixture of H2O and conc. NH3, and the precipitate formed was collected, dried, and finally purified by recrystallization from CH3CN, ethanol or toluene to give 7.
2,3-Bis[(1-(3-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy]quin oxaline (7a). Mp, 235 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 5.73 (s, 2H, 6-H), 7.60–7.63 (m, 1H, 1-H), 7.88–7.92 (m, 2H, 2,2′-H), 8.36 (ddd, J = 8.4 Hz, J = 2 Hz, J = 0.8 Hz, 1H, 1′-H), 8.40 (ddd, J = 8 Hz, J = 1.9 Hz, J = 0.8 Hz, 1H, 3′-H), 8.72 (t, J = 2 Hz, 1H, 4′-H), 9.21 (s, 1H, 5-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 59.7, 115.5, 123.7, 124.7, 126.8, 127.6, 132.0, 137.0, 137.5, 143.7, 148.9, 149.0 ppm; IR (KBr):
= 3072, 2960, 1522, 1484, 1347 cm−1. MS (m/z): 566 M+.
2,3-Bis[(1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxaline (7b). Mp, 217 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 5.74 (s, 2H, 6-H), 7.60–7.62 (m, 1H, 1-H), 7.84–7.98 (m, 4H), 8.24 (dd, J = 8.2 Hz, J = 1 Hz, 1H, 4′-H), 8.90 (s, 1H, 5-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 59.6, 126.0, 126.8, 127.4, 127.6, 128.2, 129.4, 131.7, 134.9, 137.0, 143.0, 144.5, 149.0 ppm; IR (KBr):
= 3100, 2955, 1600, 1530, 1456, 1350, 1215 cm−1. MS (m/z): 566 M+.
2,3-Bis[(1-(3-chloro-4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxaline (7c). Mp, 259–260 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 5.72 (s, 2H, 6-H), 7.59–7.63 (m, 1H, 1-H), 7.86–7.90 (m, 1H, 2-H), 8.02 (d, J = 8.8 Hz, 1H, 2′-H), 8.27 (dd, J = 8.6 Hz, J = 2.6 Hz, 1H, 1′-H), 8.68 (d, J = 2.4 Hz, 1H, 3′-H), 9.12 (s, 1H, 5-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 59.6, 117.7, 124.6, 125.1, 125.4, 126.8, 127.6, 133.5, 136.1, 137.0, 143.8, 148.4, 148.9 ppm; IR (KBr):
= 3100, 2960, 1539, 1465, 1360, 1320 cm−1. MS (m/z): 634 M+.
2,3-Bis[(1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxaline (7d). Mp, 230 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 5.70 (s, 2H, 6-H), 7.57–7.65 (m, 3H, 1′, 2′, 2-H), 7.88–7.93 (m, 2H, 1, 3′-H), 8.05 (t, J = 2 Hz, 1H, 4′-H), 9.05 (s, 1H, 5-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 59.7, 119.4, 120.6, 124.4, 126.8, 127.6, 129.1, 132.0, 134.6, 137.0, 138.0, 143.4, 149.0 ppm; IR (KBr):
= 3100, 2965, 1595, 1460, 1310, 1220 cm−1. MS (m/z): 566 M+.
General procedure for synthesis of 2-amino-3-[(1-(aryl)-1H-1,2,3-triazol-4-yl)methoxy]quinoxaline
A mixture of 6 (1 mmol) and a secondary amine (2.2 mmol) in DMF (5 mL) was stirred at 70 °C. After completion of the reaction (monitored by TLC), the solvent was evaporated, the remaining solid was washed with water and dried, and the crude product was purified by recrystallization from ethanol to give 8.
N,N-Dimethyl-3-[(1-(3-nitrophenyl)-1H-1,2,3-triazol-4-yl)meth oxy]quinoxalin-2-amine (8a). Mp, 130–131 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 3.18 (s, 6H, 7-H), 5.71 (s, 2H, 6-H), 7.37 (td, J = 7.5 Hz, J = 1.4 Hz, 1H, 3-H), 7.45 (td, J = 7.6 Hz, J = 1.4 Hz, 1H, 2-H), 7.61 (dd, J = 8 Hz, J = 1.2 Hz, 1H, 1-H), 7.72 (td, J = 8 Hz, J = 1.2 Hz, 1H, 4-H), 7.91 (t, J = 8.2 Hz, 1H, 2′-H), 8.34 (ddd, J = 8.2 Hz, J = 2.2 Hz J = 0.6 Hz, 1H, 1′-H), 8.43 (ddd, J = 8 Hz, J = 2 Hz J = 0.8 Hz, 1H, 3′-H), 8.75 (d, J = 2.2 Hz, 1H, 4′-H), 9.21 (s, 1H, 5-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 31.2, 36.2, 60.7, 117.7, 124.5, 125.1, 125.4, 127.2, 128.1, 128.5, 131.3, 133.6, 136.1, 138.4, 139.0, 139.2, 143.7, 148.5, 152.5 ppm; IR (KBr):
= 3140, 2913, 1523, 1340, 1225, 1020 cm−1. MS (m/z): 391 M+.
2-(Morpholin-4-yl)-3-[(1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl) methoxy]quinoxaline (8b). Mp, 146–147 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 3.64 (t, J = 4.6 Hz, 4H, 7-H), 3.74 (t, J = 4.6 Hz, 4H, 8-H), 5.73 (s, 2H, 6-H), 7.47–7.54 (m, 2H, 2, 3-H), 7.70 (dd, J = 7.6 Hz, J = 1.6 Hz, 1H, 1-H), 7.78 (dd, J = 7.4 Hz, J = 1.6 Hz, 1H, 4-H), 7.85–7.91 (m, 2H, 1′, 3′-H), 7.99 (td, J = 7.7 Hz, J = 1.2 Hz, 1H, 2′-H), 8.26 (dd, J = 8.2 Hz, J = 1.4 Hz, 1H, 4′-H), 8.88 (s, 1H, 5-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 48.3, 59.6, 66.3, 126.0, 126.34, 126.36, 126.47, 126.97, 127.4, 128.3, 129.6, 131.8, 134.9, 136.0, 138.3, 143.4, 144.5, 147.0, 149.8 ppm; IR (KBr):
= 3140, 2900, 1610, 1520, 1460, 1347, 1200 cm−1. MS (m/z): 433 M+.
2-[(1-(2-Nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy]-3-(piperidin-1-yl)quinoxaline (8c). Mp, 159–161 °C; 1H NMR (400 MHz, [D6] DMSO): δ = 1.63 (s, 6H, 8, 9-H), 3.62 (s, 4H, 7-H), 5.71 (s, 2H, 6-H), 7.42 (td, J = 7.6 Hz, J = 1.6 Hz, 1H, 3-H), 7.48 (td, J = 7.6 Hz, J = 1.6 Hz, 1H, 2-H), 7.65 (dd, J = 8 Hz, J = 1.2 Hz, 1H, 1-H), 7.75 (dd, J = 7.8 Hz, J = 1.2 Hz, 1H, 4-H), 7.85–7.91 (m, 2H, 1′, 2′-H), 7.96–8.00 (m, 2H, 3′-H), 8.25 (dd, J = 8 Hz, J = 1.2 Hz, 1H, 4′-H), 8.87 (s, 1H, 5-H) ppm; 13C NMR (400 MHz, [D6] DMSO): δ = 24.7, 25.8, 48.8, 59.5, 125.7, 126.0, 126.1, 126.3, 126.8, 127.2, 128.2, 129.5, 131.7, 134.9, 135.8, 138.6, 143.5, 144.5, 147.3, 149.9 ppm; IR (KBr):
= 3140, 2950, 1525, 1485, 1460, 1344, 1310, 1240 cm−1. MS (m/z): 465 M+.
Conclusion
An efficient procedure was developed for the synthesis of a 1,2,3-triazole-linked quinoxaline ring system in high-to-excellent yields by the reaction of the quinoxaline acetylenic compound 2-chloro-3-(prop-2-ynyloxy)quinoxaline or 2,3-bis(prop-2-ynyloxy)quinoxaline with aromatic azides via copper-catalyzed click reactions. Short reaction time, simple operation, and easy workup are some advantages of these protocol.
Acknowledgements
We wish to express our thanks to the Research Council of the Shahrood University of Technology for the financial support of this work.
References
-
(a) V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, Angew. Chem., Int. Ed., 2002, 114, 2708–2711 CrossRef;
(b) M. Meldal and C. W. Tornøe, Chem. Rev., 2008, 108, 2952–3015 CrossRef CAS PubMed;
(c) J. E. Hein and V. V. Fokin, Chem. Soc. Rev., 2010, 39, 1302–1315 RSC.
-
(a) M. S. Singh, S. Chowdhury and S. Koley, Tetrahedron, 2016, 72, 5257–5283 CrossRef CAS;
(b) K. Ladomenou, V. Nikolaou, G. Charalambidis and A. G. Coutsolelos, Coord. Chem. Rev., 2016, 306, 1–42 CrossRef CAS;
(c) V. K. Tiwari, B. B. Mishra, K. B. Mishra, N. Mishra, A. S. Singh and X. Chen, Chem. Rev., 2016, 116, 3086–3240 CrossRef CAS PubMed.
-
(a) T. M. Keck, A. K. Banala, R. D. Slack, C. Burzynski, A. Bonifazi, O. M. Okunola-Bakare, M. Moore, J. R. Deschamps, R. Rais and B. S. Slusher, Bioorg. Med. Chem. Lett., 2015, 23, 4000–4012 CrossRef CAS PubMed;
(b) A. Anand, M. V. Kulkarni, S. D. Joshi and S. R. Dixit, Bioorg. Med. Chem. Lett., 2016, 26, 4709–4713 CrossRef CAS PubMed.
-
(a) G. Franc and A. K. Kakkar, Chem. Soc. Rev., 2010, 39, 1536–1544 RSC;
(b) W. H. Binder and R. Sachsenhofer, Macromol. Rapid Commun., 2007, 28, 15–54 CrossRef CAS.
- P. M. E. Gramlich, C. T. Wirges, A. Manetto and T. Carell, Angew. Chem., Int. Ed., 2008, 47, 8350–8358 CrossRef CAS PubMed.
- G. C. Tron, T. Pirali, R. A. Billington, P. L. Canonico, G. Sorba and A. A. Genazzani, Med. Res. Rev., 2008, 28, 278–308 CrossRef CAS PubMed.
- H. Y. Guo, F. F. Yang, Z. Y. Jiao and J. R. Lin, Chin. Chem. Lett., 2013, 24, 450–452 CrossRef CAS.
- N. G. Aher, V. S. Pore, N. N. Mishra, A. Kumar, P. K. Shukla, A. Sharma and M. K. Bhat, Bioorg. Med. Chem. Lett., 2009, 19, 759–763 CrossRef CAS PubMed.
- J. A. Demaray, J. E. Thuener, M. N. Dawson and S. J. Sucheck, Bioorg. Med. Chem. Lett., 2008, 18, 4868–4871 CrossRef CAS PubMed.
- X. L. Wang, K. Wan and C. H. Zhou, Eur. J. Med. Chem., 2010, 45, 4631–4639 CrossRef CAS PubMed.
- D. R. Buckle, D. J. Outred, C. J. M. Rockell, H. Smith and B. A. Spicer, J. Med. Chem., 1983, 26, 251–254 CrossRef CAS PubMed.
- M. Whiting, J. C. Tripp, Y. C. Lin, W. Lindstrom, A. J. Olson, J. H. Elder, K. B. Sharpless and V. V. Fokin, J. Med. Chem., 2006, 4, 7697–7710 CrossRef PubMed.
- M. J. Giffin, H. Heaslet, A. Brik, Y. C. Lin, G. Cauvi, C. H. Wong, D. E. McRee, J. H. Elder, C. D. Stout and B. E. Torbett, J. Med. Chem., 2008, 51, 6263–6270 CrossRef CAS PubMed.
- M. S. Costa, N. Boechat, E. A. Rangel, F. D. C. D. Silva, A. M. T. D. Souza, C. R. Rodrigues, H. C. Castro, I. N. Junior, M. C. S. Lourenc, S. M. S. V. Wardell and V. F. Ferreirab, Bioorg. Med. Chem., 2006, 14, 8644–8653 CrossRef CAS PubMed.
- S. R. Patpi, L. Pulipati, P. Yogeeswari, D. Sriram, N. Jain, B. Sridhar, R. Murthy, D. T. Anjana, S. V. Kalivendi and S. Kantevar, J. Med. Chem., 2012, 55, 3911–3922 CrossRef CAS PubMed.
- R. D. Simone, M. G. Chini, I. Bruno, R. Riccio, D. Mueller, O. Werz and G. Bifulco, J. Med. Chem., 2011, 54, 1565–1575 CrossRef PubMed.
- C. W. Lindsley, Z. Zhao, W. H. Leister, R. G. Robinson, S. F. Barnett, D. Defeo-Jones, R. E. Jones, G. D. Hartman, J. R. Huff, H. E. Huber and M. E. Duggan, Bioorg. Med. Chem. Lett., 2005, 15, 761–764 CrossRef CAS PubMed.
- M. Loriga, S. Piras, P. Sanna and G. Paglietti, Farmaco, 1997, 52, 157–166 CAS.
- L. E. Seitz, W. J. Suling and R. C. Reynolds, J. Med. Chem., 2002, 45, 5604–5606 CrossRef CAS PubMed.
-
(a) W. He, M. R. Meyers, B. Hanney, A. Spada, G. Blider, H. Galzeinski, D. Amin, S. Needle, K. Page, Z. Jayyosi and H. Perrone, Bioorg. Med. Chem. Lett., 2003, 13, 3097–3100 CrossRef CAS PubMed;
(b) Y. B. Kim, Y. H. Kim, J. Y. Park and S. K. Kim, Bioorg. Med. Chem. Lett., 2004, 14, 541–544 CrossRef CAS PubMed.
- J. Lee, W. V. Murray and R. A. Rivero, J. Org. Chem., 1997, 62, 3874–3879 CrossRef CAS.
- R. J. Holland, I. R. Hardcastle and M. Jarman, Tetrahedron Lett., 2002, 43, 6435–6437 CrossRef CAS.
- V. Krchnak, J. Smith and J. Vagner, Tetrahedron Lett., 2000, 41, 2835–2838 CrossRef CAS.
- T. Uxey, P. Tempest and C. Hulme, Tetrahedron Lett., 2002, 43, 1637–1639 CrossRef.
- F. Zaragoza and H. Stephensen, J. Org. Chem., 1999, 64, 2555–2557 CrossRef CAS.
- A. Dell, D. H. William, H. R. Morris, G. A. Smith, J. Feeney and G. C. K. Roberts, J. Am. Chem. Soc., 1975, 97, 2497–2502 CrossRef CAS PubMed.
- C. Bailly, S. Echepare, F. Gago and M. Waring, Anti-Cancer Drug Des., 1999, 14, 291–303 CAS.
- S. A. Raw, C. D. Wilfred and R. J. K. Taylor, Chem. Commun., 2003, 2286–2287 RSC.
- M. J. Fray, D. J. Bull, C. L. Carr, E. C. L. Gautier, C. E. Mowbray and A. Stobie, J. Med. Chem., 2001, 44, 1951–1962 CrossRef CAS PubMed.
- R. Huigsen, G. Szeimies and L. Möbius, Chem. Ber., 1967, 100, 2494–2507 CrossRef.
- V. O. Rodionov, S. I. Presolski, S. Gardinier, Y.-H. Lim and M. G. Finn, J. Am. Chem. Soc., 2007, 129, 12696–12704 CrossRef CAS PubMed.
- A. Keivanloo, M. Bakherad and A. Rahimi, Synthesis, 2010, 1599–1602 CrossRef CAS.
- M. Bakherad, A. Keivanloo and S. Samangooei, Tetrahedron Lett., 2012, 23, 1447–1449 CrossRef.
- M. Bakherad, A. Keivanloo and S. Jajarmi, Tetrahedron, 2012, 68, 2107–2112 CrossRef CAS.
-
(a) C. Ornelas, J. Ruiz Aranzaes, E. Cloutet, S. Alves and D. Astruc, Angew. Chem., Int. Ed., 2007, 119, 890–895 CrossRef;
(b) D. Astruc, L. Liang, A. Rapakousiou and J. Ruiz, Acc. Chem. Res., 2011, 45, 630–640 CrossRef PubMed.
- J. E. Hein and V. V. Fokin, Chem. Soc. Rev., 2010, 39, 1302–1315 RSC.
-
(a) V. O. Rodionov, S. I. Presolski, S. Gardinier, Y.-H. Lim and M. Finn, J. Am. Chem. Soc., 2007, 129, 12696–12704 CrossRef CAS PubMed;
(b) V. Hong, S. I. Presolski, C. Ma and M. Finn, Angew. Chem., Int. Ed., 2009, 48, 9879–9883 CrossRef CAS PubMed;
(c) N. Candelon, D. Lastécouères, A. K. Diallo, J. R. Aranzaes, D. Astruc and J.-M. Vincent, Chem. Commun., 2008, 741–743 RSC;
(d) L. Liang, J. Ruiz and D. Astruc, Adv. Synth. Catal., 2011, 353, 3434–3450 CrossRef CAS.
- C. Deraedt, N. l. Pinaud and D. Astruc, J. Am. Chem. Soc., 2014, 136, 12092–12098 CrossRef CAS PubMed.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ra22603e |
|
This journal is © The Royal Society of Chemistry 2016 |
Click here to see how this site uses Cookies. View our privacy policy here.